Phase I/II study to evaluate systemic durvalumab plus intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results Meeting Abstract

  

Authors:	Zamarin, D.; Odunsi, K.; Slomovitz, B. M.; Duska, L. R.; Nemunaitis, J. J.; Reilley, M.; Bykov, Y.; Holland, A.; Hubbard-Lucey, V. M.; Shohara, L.; Schwarzenberger, P.; Ricciardi, T.; Macri, M. J.; Ryan, A.; Jaderberg, M. E.; Venhaus, R. R.
Abstract Title:	Phase I/II study to evaluate systemic durvalumab plus intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results
Meeting Title:	56th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	38
Issue:	15 Suppl.
Meeting Dates:	2020 May 29-31
Meeting Location:	Virtual Conference
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2020-05-20
Language:	English
ACCESSION:	WOS:000560368301280
PROVIDER:	wos
DOI:	10.1200/JCO.2020.38.15_suppl.3017
Notes:	Meeting Abstract: 3017 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/173019